Company-wide revenue
Reported revenue in 2021 ¥361.36B Reported revenue in 2025 ¥515.78B
- growth amount
- +¥154.42B
- growth annualized
- +9.3%
- growth total
- +42.7%
Japanese company profile · 4528
ONO PHARMACEUTICAL CO., LTD.
In its FY2025 public filing, ONO PHARMACEUTICAL CO., LTD. reports Pharmaceutical business (research and development, import, manufacture, and sale). The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 小野薬品工業株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
ONO PHARMACEUTICAL CO., LTD.'s largest reported business by revenue in FY2025 was Pharmaceutical business (research and development, import, manufacture, and sale).
The business with the highest reported segment profit in FY2025 was Pharmaceutical business (research and development, import, manufacture, and sale).
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Segment revenue | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Pharmaceutical business (research and development, import, manufacture, and sale) | ¥515.78B ↗ | 100.0% | ¥92.24B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Business label unavailable in English
- 病気と苦痛に対する人間の闘いのために
- Pharmaceutical business (research and development, import, manufacture, and sale)
- 医薬品事業（研究開発、仕入、製造、販売）
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Business label unavailable in English
- 病気と苦痛に対する人間の闘いのために
- Pharmaceutical business (research and development, import, manufacture, and sale)
- 医薬品事業（研究開発、仕入、製造、販売）
- Segment revenue
- セグメント収益
- Segment profit (loss)
- セグメント利益（損失）
What is growing?
What is growing?
Business revenue growth
Pharmaceutical business (research and development, import, manufacture, and sale)
Reported revenue in 2021 ¥361.36B Reported revenue in 2025 ¥515.78B
- growth amount
- +¥154.42B
- growth annualized
- +9.3%
- growth total
- +42.7%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YA20
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.